# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HSBC analyst Morten Herholdt maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $339 to $342.
Oppenheimer analyst Jay Olson maintains Biogen (NASDAQ:BIIB) with a Outperform and maintains $270 price target.
With the earnings season now halfway through, the percentage of S&P 500 companies reporting positive earnings surprises and...
Barclays analyst Carter Gould maintains Biogen (NASDAQ:BIIB) with a Equal-Weight and lowers the price target from $215 to $200.
Wedbush analyst Laura Chico maintains Biogen (NASDAQ:BIIB) with a Neutral and raises the price target from $213 to $215.
HC Wainwright & Co. analyst Andrew Fein maintains Biogen (NASDAQ:BIIB) with a Buy and lowers the price target from $325 ...